Chemophase
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Superficial Bladder Cancer
Conditions
Superficial Bladder Cancer
Trial Timeline
Oct 1, 2008 → Aug 1, 2009
NCT ID
NCT00782587About Chemophase
Chemophase is a phase 1 stage product being developed by Halozyme Therapeutics for Superficial Bladder Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00782587. Target conditions include Superficial Bladder Cancer.
What happened to similar drugs?
2 of 5 similar drugs in Superficial Bladder Cancer were approved
Approved (2) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00782587 | Phase 1 | Completed |
Competing Products
11 competing products in Superficial Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EG-70 (phase 1) + EG-70 (phase 2) | enGene | Phase 1/2 | 29 |
| Gemcitabine | Eli Lilly | Phase 2 | 35 |
| Gemcitabine + mitomycin C | Eli Lilly | Phase 2 | 35 |
| MK-3475 and BCG | Merck | Phase 2 | 42 |
| Diclofenac gel | Novartis | Approved | 43 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 27 |
| Dalteparin sodium injection | Pfizer | Approved | 43 |
| Rivaroxaban + Fondaparinux | Bayer | Phase 3 | 37 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 37 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Relmada Therapeutics | Phase 3 | 26 |
| EscharEx 5% (EX-02 formulation) | MediWound | Phase 1/2 | 29 |